TruSight Oncology 500 ctDNA

Assay targeting multiple somatic variant types from plasma, including microsatellite instability (MSI) and tumor mutational burden (TMB). Read More...
Select Product(s)
Library Prep

TruSight Oncology 500 ctDNA Kit (48 samples)

20039252

Price
 
 

TruSight Oncology 500 ctDNA Kit plus Pierian Interpretation Report (16 indexes, 48 Samples)

20043410

Price
 
 

Reagents

NovaSeq 6000 S2 Reagent Kit v1.5 (300 cycles)

20028314

Price
 
 

NovaSeq 6000 S4 Reagent Kit v1.5 (300 cycles)

20028312

Price
 
 

NovaSeq XP 4-Lane Kit v1.5

20043131

Price
 
 

Software and Informatics Options

Illumina DRAGEN Server v3

20040619

Price
 
 

Illumina DRAGEN Server v4

20051343

Price
 
 

ICA Basic Annual Subscription

20044874

ICA Professional Annual Subscription

20044876

ICA Enterprise Annual Subscription

20038994

ICA Enterprise Service and Compliance Add-on (applies to Basic only)

20066830

Illumina Analytics - 1 iCredit

20042038

Price
 
 

Illumina Analytics Starter Package - 1,000 iCredits

20042039

Price
 
 

Illumina Analytics - 5,000 iCredit

20042040

Price
 
 

Illumina Analytics - 50,000 iCredit

20042041

Price
 
 

Illumina Analytics - 100,000 iCredit

20042042

Price
 
 

DRAGEN TruSight Oncology 500 ctDNA Analysis Software, On-Premise, Level 8, 1 Year License

20042107


Services

TruSight Oncology 500 ctDNA training

20045347

Product Highlights

TruSight Oncology ctDNA is a pan-cancer next-generation sequencing (NGS) assay that enables in-house comprehensive genomic profiling (CGP) from blood plasma.

The broad panel is designed with similar DNA content as its tissue counterparts (TruSight Oncology 500 and TruSight Oncology 500 High-Throughput), including key immuno-oncology (IO) biomarkers, making it ideal to utilize in conjunction with or without precious tissue samples.

Enable Comprehensive Genomic Profiling from Plasma

  • Pan-cancer CGP assay aligned with key guidelines and trials
  • Similar DNA content as TruSight Oncology 500, including full coding sequence of 523 genes
  • Detects single nucleotide variants (SNVs), Indels, CNVs, fusions, and IO biomarkers

Implement In-house CGP with an Integrated Workflow

  • Streamlined 5-day workflow from cfDNA results
  • Rapid variant calling algorithm powered by DRAGEN Bio-IT Platform, available locally on DRAGEN server
  • Secure, scalable, cloud-based variant analysis is available with DRAGEN pipelines on Illumina Connected Analytics (ICA)
  • Integrated interpretation report available through Clinical Genomics Workspace from Pierian

Achieve Confidence in Results

  • More confident results with hybrid-capture chemistry, unique molecular indices (UMI) and sophisticated error correction
  • Inclusive of unique molecular indexes (UMIs) for high sensitivity in variant detection
  • Deep sequencing provided by the NovaSeq 6000 and more affordability with the v1.5 Reagent Kits

Unlock Liquid Biopsy, Including Valuable IO Insights

  • Obtain the analytical sensitivity and specificity required for low-level variant detection in plasma
  • Unlock CGP insights from liquid biopsy with or without precious tissue samples
  • Broad 1.94 Mb panel ideal for IO biomarkers such as TMB and MSI (now with >2400 homopolymer sites)
Learn more about the TruSight Oncology Product Family
Liquid Biopsy Offers Advantages in the Modern Age

Innovations in molecular assays enable comprehensive, precise analysis of cell-free DNA.

Read Application Spotlight
Liquid Biopsy Offers Advantages in the Modern Age

TruSight Oncology 500 Portfolio

All three TruSight Oncology 500 assays are designed to identify key biomarkers in guidelines and clinical trials.

TruSight Oncology 500 Assay

Assess key cancer biomarkers from FFPE tumor tissue with the TruSight Oncology 500 Assay.

TruSight Oncology 500 High-Throughput Assay

Batch up to 192 samples at a time while using the same biomarkers and tissue type as the TruSight Oncology 500 assay.

TruSight Oncology 500 ctDNA Assay

Analyze circulating tumor DNA from plasma with the TruSight Oncology 500 ctDNA assay.

Have questions about our products? Connect with an Illumina representative.

Frequently Purchased Together

Specifications

Project Recommendations

Instrument Recommended Number of Samples Read Length
NovaSeq 6000 System 24 samples per run (S4 flow cell), 800M paired-end reads, 35,000x coverage 2 × 150 bp
NovaSeq 6000 System 8 samples per run (S2 flow cell), 800M paired-end reads, 35,000x coverage 2 × 150 bp

Product Comparison

TruSight Oncology 500 ctDNA TruSight Oncology 500 TruSight Oncology 500 High-Throughput
Cancer Type Pan-Cancer Pan-Cancer Pan-Cancer
Content Specifications Targeted selection of 523 genes (full coding sequence) for a total of 1.94Mb panel size.
• Guideline Coverage: Broad coverage of key guidelines for multiple solid tumor types
• Immuno-oncology Biomarker Coverage: TMB and MSI*
Targeted selection of DNA from 523 genes of interest, and RNA from 55 genes, for a total of 1.94Mb panel size.
• Guideline Coverage: Broad coverage of key guidelines for multiple solid tumor types
• Clinical Trials Coverage: Over 1,000 clinical trials
• Immuno-oncology Biomarker Coverage: Biomarkers TMB and MSI included; also inclusive of HLA regions, POLE1 and POLD1*.
• TruSight Oncology 500 HRD** kit content includes coverage of ~25,000 SNP's to assess homologous recombination deficiency through a comprehensive genomic instability score (LOH+TAI+LST), powered by Myriad Genetics.
• TruSight Oncology 500 HRD** is an optional add-on kit to TruSight Oncology 500.

**Not available in the US or Japan
Targeted selection of DNA from 523 genes of interest, and RNA from 55 genes, for a total of 1.94Mb panel size.
• Guideline Coverage: Broad coverage of key guidelines for multiple solid tumor types
• Clinical Trials Coverage: Over 1,000 clinical trials
• Immuno-oncology Biomarker Coverage: Biomarkers TMB and MSI included; also inclusive of HLA regions, POLE1 and POLD1*.
Hands-On Time Manual: ~10.5 hrs
Automated: N/A
Manual: ~10.5 hrs
Automated: ~2.5 hrs (TruSight Oncology 500 only)
Manual: ~10.5 hrs
Automated: ~2.5 hrs
Input Quantity 30 ng cfDNA (8-10 ml of plasma) 40 ng DNA, 40 ng RNA 40 ng DNA, 40-80 ng RNA (need at least 2 mm3 FFPE tissue)
Method Target Enrichment, Target Enrichment, Targeted DNA Sequencing Target Enrichment, Target Enrichment, Targeted DNA Sequencing, Targeted RNA Sequencing Target Enrichment, Target Enrichment, Targeted DNA Sequencing, Targeted RNA Sequencing
Nucleic Acid Type DNA RNA, DNA RNA, DNA
Specialized Sample Types Blood, Circulating Tumor DNA FFPE Tissue FFPE Tissue
Species Category Human Human Human
System Compatibility NovaSeq 6000 NextSeq 500, NextSeq 550, NextSeq 550Dx in Research Mode NovaSeq 6000
Technology Sequencing Sequencing Sequencing
Variant Class Copy Number Variants (CNVs), Gene Fusions, Insertions-Deletions (indels), Single Nucleotide Variants (SNVs), Somatic Variants Copy Number Variants (CNVs), Gene Fusions, Insertions-Deletions (indels), Single Nucleotide Variants (SNVs), Transcript Variants Copy Number Variants (CNVs), Gene Fusions, Insertions-Deletions (indels), Single Nucleotide Variants (SNVs), Transcript Variants

Based on PierianDx Clinical Genomics Knowledgebase, as of March 2020.

Method-Specific Workflow Example

 

Supporting Data and Figures

 

Related Products